Selecta Biosciences (SELB) Misses Q3 EPS by 9c; Reports Cash and Cash Equivalents of $140.0M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
November 9, 2021 8:00 AM EST-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform-
-Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR); Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline-
-Continued execution of multiple preclinical programs toward IND-
-Further strengthened leadership team with the appointment of Kevin Tan as CFO-
-As of September 30, 2021, Selecta had approximately $140.0 million in cash, cash equivalents, restricted cash and marketable securities which is expected to provide runway... More
